Insiders Palvella Therapeutics, Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-12 pm EDT			5-day change	1st Jan Change
136.60 ^USD	-2.21%		+1.22%	+30.51%

Mar. 02	Palvella Therapeutics Insider Bought Shares Worth $300,000, According to a Recent SEC Filing	MT
Mar. 02	Palvella Therapeutics Insider Bought Shares Worth $500,000, According to a Recent SEC Filing	MT

Mar. 02	Palvella Therapeutics Insider Bought Shares Worth $300,000, According to a Recent SEC Filing	MT
Mar. 02	Palvella Therapeutics Insider Bought Shares Worth $500,000, According to a Recent SEC Filing	MT
Jan. 07	Palvella Therapeutics, Inc. Appoints Vimal Patel as Senior Vice President of Medical Affairs	CI
25-09-03	Palvella Therapeutics, Inc. Appoints David W. Osborne as Chief Innovation Officer, Effective 03 September 2025	CI
25-09-03	Palvella Therapeutics strengthens leadership with appointment of accomplished scientist and biopharmaceutical executive David W. Osborne, Ph.D. as chief innovation officer	RE
25-05-27	Palvella Therapeutics Appoints Rare Disease Commercial Veteran Ashley Kline As Chief Commercial Officer	RE
25-05-27	Palvella Therapeutics, Inc. Appoints Ashley Kline as Chief Commercial Officer, Effective May 27, 2025	CI